CureVac Stock

CureVac Debt 2024

CureVac Debt

-360.63 EUR

Ticker

CVAC

ISIN

NL0015436031

WKN

A2P71U

In 2024, CureVac's total debt was -360.63 EUR, a -20.51% change from the -453.7 EUR total debt recorded in the previous year.

CureVac Aktienanalyse

What does CureVac do?

CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding CureVac's Debt Structure

CureVac's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing CureVac's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to CureVac’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in CureVac’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about CureVac stock

What is the debt of CureVac this year?

CureVac has a debt level of -360.63 EUR this year.

What was the debt of CureVac compared to the previous year?

The debt of CureVac has increased by -20.51% compared to the previous year dropped.

What are the consequences of high debt for investors in CureVac?

High debt can pose a risk for investors of CureVac, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of CureVac?

Low debt means that CureVac has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from CureVac affect the company?

An increase in debt of CureVac can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of CureVac affect the company?

A reduction in debt of CureVac can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of CureVac?

Some factors that can influence the debt of CureVac include investments, acquisitions, operating costs, and revenue development.

Why are the debts of CureVac so important for investors?

The debts of CureVac are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can CureVac take to change the debt?

To change the debt, CureVac can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does CureVac pay?

Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.

What is the dividend yield of CureVac?

The current dividend yield of CureVac is .

When does CureVac pay dividends?

CureVac pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CureVac?

CureVac paid dividends every year for the past 0 years.

What is the dividend of CureVac?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is CureVac located?

CureVac is assigned to the 'Health' sector.

Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CureVac from 12/19/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did CureVac pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of CureVac in the year 2023?

In the year 2023, CureVac distributed 0 EUR as dividends.

In which currency does CureVac pay out the dividend?

The dividends of CureVac are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The CureVac stock can be added to a savings plan with the following providers: Scalable Capital

Andere Kennzahlen von CureVac

Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.